AstraZeneca plc (AZN) Given a GBX 3,800 Price Target by Goldman Sachs Group, Inc. (The) Analysts
Goldman Sachs Group, Inc. (The) set a GBX 3,800 ($50.15) target price on AstraZeneca plc (LON:AZN) in a research report released on Thursday morning. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. Berenberg Bank reissued a buy rating and set a GBX 5,800 ($76.54) price objective on shares of AstraZeneca plc in a research report on Wednesday, November 1st. HSBC Holdings plc lifted their price objective on AstraZeneca plc from GBX 4,150 ($54.76) to GBX 4,340 ($57.27) and gave the company a reduce rating in a research report on Wednesday, November 1st. Deutsche Bank AG reissued a buy rating and set a GBX 5,600 ($73.90) price objective on shares of AstraZeneca plc in a research report on Wednesday, November 1st. Kepler Capital Markets lifted their price objective on AstraZeneca plc from GBX 5,200 ($68.62) to GBX 5,250 ($69.28) and gave the company a buy rating in a research report on Wednesday, November 1st. Finally, J P Morgan Chase & Co reissued a neutral rating on shares of AstraZeneca plc in a research report on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,183.55 ($68.40).
Shares of AstraZeneca plc (AZN) opened at GBX 5,171 ($68.24) on Thursday. AstraZeneca plc has a 12-month low of GBX 3,996 ($52.73) and a 12-month high of GBX 5,520 ($72.84).
TRADEMARK VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-given-a-gbx-3800-price-target-by-goldman-sachs-group-inc-the-analysts/1681825.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.